Experimental HIV Drugs
Experimental HIV Drugs
Elvitegravir 'Quad' Single-tablet Regimen Shows Continued HIV Suppression at 48 Weeks
- Details
- Category: HIV Treatment
- Published on Tuesday, 14 September 2010 16:46
- Written by Liz Highleyman
Gilead Science's experimental "Quad" pill -- a once-daily single-tablet coformulation containing the new integrase inhibitor elvitegravir, the novel boosting agent cobicistat (GS 9350), and tenofovir plus emtricitabine (the drugs in the Truvada pill) -- continued to demonstrate potent antiviral activity and good tolerability at 48 weeks, according to data presented this week at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2010). In a second comparison, cobicistat worked as well as ritonavir as a booster for atazanavir, with similar changes in kidney function.
New NRTI Festinavir Exhibits Good Anti-HIV Activity and Safety in Phase 1b/2a Study
- Details
- Category: HIV Treatment
- Published on Tuesday, 14 September 2010 13:46
- Written by Liz Highleyman
The new nucleoside reverse transcriptase inhibitor (NRTI) festinavir, or OBP-601, demonstrated good antiviral activity, lowering HIV viral load by more than 1 log over 10 days, researchers reported this week at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2010) in Boston. The new drug, which is related to stavudine (d4T, Zerit), was associated with few serious drug-related adverse events in this short-term study, but longer clinical trials are needed.
More Promising Data on GSK572 Integrase Inhibitor, Phase 3 Studies to Begin Soon
- Details
- Category: HIV Treatment
- Published on Friday, 23 July 2010 13:56
- Written by Liz Highleyman
S/GSK1349572 (better known as GSK572), the second-generation integrase inhibitor being developed jointly by Shionogi and ViiV Healthcare, continues to show potent antiviral activity with good tolerability, according to 2 studies presented at the XVIII International AIDS Conference (AIDS 2010) this week in Vienna. GSK572 worked against HIV with some raltegravir resistance mutations and has a high genetic barrier to resistance itself. Based on these findings, the companies announced the drug would soon enter Phase 3 trials.
AIDS 2010: Investigational HIV Drug TBR-652 Reduces Viral Replication and May Dampen Inflammation
- Details
- Category: Experimental HIV Drugs
- Published on Tuesday, 03 August 2010 13:56
- Written by Liz Highleyman
Tobira Pharmaceuticals' TBR-652, an experimental drug that blocks both the CCR5 and CCR2 cell surface receptors, has the dual effect of inhibiting HIV and affecting a biomarker associated with inflammation, according to data presented at the XVIII International AIDS Conference (AIDS 2010) last month in Vienna. TBR-652 was generally well-tolerated and a Phase 2b clinical trial is planned for early next year.
Monoclonal Antibody PRO 140 Suppresses HIV Viral Load with Once-weekly Dosing
- Details
- Category: Experimental HIV Drugs
- Published on Friday, 07 May 2010 00:00
- Written by Liz Highleyman
Subcutaneous injections of PRO 140, a humanized monoclonal antibody that blocks the CCR5 co-receptor and inhibits HIV entry into cells, reduced viral load significantly more than placebo, according to a study described in the May 15, 2010 Journal of Infectious Diseases. PRO 140 worked well when administered once-weekly, offering proof-of-concept for an antiretroviral therapy that can be taken less often than current drugs.
More Articles...
- Gilead Begins First Phase 3 Clinical Trials of Boosted Elvitegravir Quad Pill
- CROI 2010: LEDGF/p75 Integrase Inhibitors and Capsid Assembly Inhibitors Offer New Approaches for Blocking HIV Replication
- CROI 2010: Investigational Drug TBR-652 Demonstrates Dual Activity against CCR5 and CCR2 Co-receptors
- Experimental CCR5 Antagonist Vicriviroc Appears Safe and Well Tolerated in HIV/HCV Coinfected Patients
Web Design and Development by